Our work also uncovered that β-arrestin mediated transactivation between PAR2 and EGFR in gefitinib-resistant NSCLC since inhibition of β-arrestin immediately impaired phosphorylation of EGFR and ERK (Figures 4A–D). This evidence concerns the gene F2RL1 and non-small cell lung carcinoma.